Quick Answer
Benchmarking clinical study startup means comparing your internal cycle times over time (you vs you) and against external industry averages (you vs others).
To do it right:
- Internal: Track 3+ quarters. Improvement = 10%+ reduction in cycle time
- External: Compare to Tufts median (89 days, 2023) and percentile bands (60-120 days)
- Context: Aim for 70%+ “active time” ratio (work vs. idle handoffs)
This helps you distinguish genuine improvement from normalized inefficiency.
Why This Matters
Last week, we explored the “5 Study Startup Metrics That Actually Predict Delays”. That post showed what to measure — but not how to interpret the numbers.
This follow-up answers that next big question:
“Okay, we tracked our startup cycle time — but how do we know if it’s actually good?”
Without a benchmark, most teams are flying blind. You might think you’re fast, when you’re just less slow than last quarter.
⚠️ The Normalized Delay Trap
When everyone in your organization accepts 90-day startup as “fast,” you’ve normalized inefficiency.
The danger: Your team celebrates hitting 85 days — without realizing high-performing sites consistently achieve 55-60 days for similar studies.
Benchmarking breaks this illusion. It shows you what “good” actually looks like, not just what feels acceptable.
Real-World Example: Site ABC’s Benchmarking Journey
Let’s walk through a complete example to see how this works in practice.
The Starting Point
Site ABC, a mid-sized academic medical center, started tracking their study startup metrics in Q1 2024. They had no idea if their performance was competitive.
Their Q1-Q3 Data:
| Study ID | Phase | Therapeutic Area | Q1 Days | Q2 Days | Q3 Days |
|---|---|---|---|---|---|
| Study 001 | 2 | Oncology | 92 | 78 | 71 |
| Study 002 | 3 | Cardiology | 85 | 82 | 68 |
| Study 003 | 2 | Neurology | 98 | 88 | 75 |
| Study 004 | 1 | Oncology | 67 | 58 | 52 |
| Study 005 | 3 | Immunology | 105 | 95 | 82 |
| Study 006 | 2 | Rare Disease | 88 | 79 | 73 |
| Study 007 | 3 | Endocrinology | 93 | 85 | 77 |
| Study 008 | 2 | Infectious Disease | 81 | 76 | 69 |
Average Cycle Time:
- Q1: 88.6 days
- Q2: 80.1 days
- Q3: 70.9 days
Step 1: Internal Benchmarking (You vs You)
Site ABC calculated their quarter-over-quarter improvement:
- Q1 → Q2: 9.6% reduction (88.6 → 80.1 days)
- Q2 → Q3: 11.5% reduction (80.1 → 70.9 days)
- Overall Q1 → Q3: 20% reduction
What they learned:
- Consistent improvement trend
- Process changes implemented in Q2 showed results in Q3
- But were they actually competitive?
Step 2: External Benchmarking (You vs Industry)
Site ABC compared their Q3 average (70.9 days) against industry benchmarks:
For Phase 2-3 Studies:
- Industry Median: 89 days (Tufts CSDD 2023)
- Top Quartile: <60 days
- Site ABC Phase 2-3 Average: 72.4 days
What they learned:
- 20% faster than industry median
- Still not in the top quartile
- Target identified: Get Phase 2-3 studies under 60 days
Step 3: Contextual Benchmarking (Efficiency Analysis)
They picked Study 006 (Rare Disease, Q3: 73 days) and broke down time allocation:
Time Breakdown:
- Active Work: 52 days
- Site review & assessment: 8 days
- Contract negotiation: 12 days
- Budget finalization: 6 days
- IRB preparation & submission: 14 days
- Protocol training & startup: 12 days
- Idle Time: 21 days
- Waiting for sponsor contract: 9 days
- Waiting for IRB response: 7 days
- Internal handoff delays: 5 days
Efficiency Rate: 52 ÷ 73 = 71.2%
What they learned:
- 71% efficiency is above industry average (60%)
- Biggest opportunity: Sponsor contract turnaround (9 days idle)
- Secondary opportunity: Internal handoff process (5 days)
The Action They Took
Based on their benchmarking analysis:
- Addressed sponsor delays: Created pre-negotiated contract templates → Reduced sponsor wait from 9 to 4 days
- Fixed internal handoffs: Implemented automated notifications → Reduced handoff delays from 5 to 2 days
- Set quarterly targets: Goal to reach top quartile (<60 days) by Q2 2025
Projected Impact: 7-day reduction = 63-day average (entering top quartile territory)
Understanding the Three Types of Benchmarking
Now that you’ve seen how it works in practice, let’s break down each type in detail.
1. Internal Benchmarking (You vs You)
What It Means
Internal benchmarking measures your own progress over time. It’s your personal baseline for improvement.
How to Apply It
- Track startup cycle times quarter-over-quarter
- Normalize for study type (Phase, therapeutic area, sponsor complexity)
- Highlight directional progress — not perfection
📊 Example:
“Feasibility response time dropped from 8.4 → 6.1 days in Q2 — a 27% improvement.”
Pro Tip: Visualize this with a simple sparkline or line chart showing quarter-over-quarter gains.
What Good Looks Like
Quarterly Reduction
Consecutive Quarters
Trend Not Spike
Why Internal Benchmarking Matters
Even if you’re slower than the industry, internal benchmarking shows:
- Your process improvements are working
- Team changes are having an impact
- You’re moving in the right direction
It builds team morale and proves ROI on optimization efforts.
But internal trends only tell half the story. You might be improving quarter-over-quarter while still lagging the industry.
2. External Benchmarking (You vs Industry)
Why It Matters
You can’t gauge performance in a vacuum. External benchmarking tells you how you stack up against industry norms.
Sources to Use
- Tufts CSDD (2023): Median startup cycle ≈ 89 days
- TransCelerate BioPharma (2024): 25th–75th percentile range often 60–120 days
- CenterWatch (2024): High-performing sites average 20-30% faster than median
- Industry Reports: Top quartile sites consistently achieve 55-65 days for Phase 2-3 studies
How to Use It
Create a bar chart comparing your internal median (purple) vs industry median (gray).
Callout Example:
“Your average contract turnaround is 27% faster than industry median.”
What Good Looks Like
Top Quartile (25th)
Industry Median
Bottom Quartile (75th)
If you’re consistently above 100 days for Phase 2-3 studies, you’re in the slower half.
Phase-Specific External Benchmarks
Not all studies are equal. Here’s what competitive looks like by phase:
Phase 1 Studies
- Top Quartile: 35-45 days
- Industry Median: 60-70 days
- Why shorter? Smaller scale, fewer requirements, less regulatory complexity
Phase 2 Studies
- Top Quartile: 50-60 days
- Industry Median: 80-90 days
- Complexity factors: Protocol complexity, patient population, special monitoring
Phase 3 Studies
- Top Quartile: 55-65 days
- Industry Median: 85-100 days
- Complexity factors: Scale requirements, regulatory burden, site infrastructure needs
Phase 4 (Post-Market) Studies
- Top Quartile: 40-50 days
- Industry Median: 65-80 days
- Why potentially shorter? Less regulatory oversight, simpler protocols
Key Insight: Always compare apples to apples. A 65-day Phase 3 startup is top-quartile performance, but the same timeline for Phase 1 is only median.
Even industry averages can mislead. A 90-day startup isn’t impressive if 40 days were wasted waiting.
3. Contextual Benchmarking (Efficiency over Duration)
Why Averages Mislead
Not all 90-day startups are equal. A 90-day timeline where 70 days are active work is far better than one with 50 days idle time.
What to Measure Instead
- % of total time in active work vs idle handoffs
- Stakeholder-specific latency (Sponsor, CRO, IRB, Site)
- Relative efficiency, not absolute duration
The Efficiency Formula
🟣 Example Breakdown:
- Total startup days: 60
- Active work days: 42 (responding, reviewing, negotiating)
- Idle days: 18 (waiting for approvals, handoffs, email lag)
- Efficiency Rate: 70%
“Of our 60 total startup days, 42 were productive and 18 were idle — a 70% active efficiency rate.”
What Good Looks Like
High-Performing
Industry Average
Significant Drag
Pro Tip: Track where idle time accumulates — sponsor delays? IRB backlog? Internal handoffs? This tells you where to focus improvement efforts.
Stakeholder-Specific Latency Tracking
Break down idle time by responsible party:
| Stakeholder | Idle Days | % of Total Idle | Action Needed |
|---|---|---|---|
| Sponsor | 9 | 43% | Pre-negotiated templates |
| IRB | 7 | 33% | Earlier submission |
| Internal Site | 5 | 24% | Process automation |
This pinpoints exactly where to focus optimization efforts.
Common Diagnostic Patterns: What Your Data Is Telling You
Here are the most common patterns we see and what they mean:
Pattern 1: High Total Days + Low Efficiency (<50%)
What it means: Your process has significant idle time and handoff problems.
Example: 95-day average with 42 days active work (44% efficiency)
Root causes:
- Too many approval layers
- Unclear ownership of tasks
- Manual handoffs causing delays
- People waiting for “someone else” to act
Fix: Map your entire workflow, identify handoff points, implement automated notifications, clarify ownership.
Pattern 2: Good Internal Improvement + Still Slow Externally
What it means: You’re getting better, but you started from a very low baseline.
Example: Improved from 120 → 95 days (21% reduction), but still above industry median of 89 days
Root causes:
- Systemic organizational inefficiencies
- Legacy processes that need overhaul
- Lack of modern tools/technology
- Insufficient staffing
Fix: Celebrate the progress, but acknowledge you’re still playing catch-up. Consider process redesign, not just optimization.
Pattern 3: Fast Cycle Time + High Efficiency + Declining Trend
What it means: You achieved excellence, but now you’re regressing.
Example: Started at 58 days/75% efficiency, now at 68 days/65% efficiency
Root causes:
- Staff turnover (lost institutional knowledge)
- Increased study complexity
- Sponsor changes (different templates, processes)
- Team complacency
Fix: Re-train team, document best practices, investigate what changed between peak and current performance.
Pattern 4: Inconsistent Performance (High Variance)
What it means: Your process isn’t standardized; outcomes depend on who’s working it.
Example: Study times range from 55-120 days with no clear pattern
Root causes:
- No standard operating procedures
- Different team members use different approaches
- Sponsor-specific variations not accounted for
- No process documentation
Fix: Create SOPs, implement process standardization, train team on consistent approach.
Pattern 5: External Competitive + Internal Plateau
What it means: You’re industry-competitive but stopped improving.
Example: Holding steady at 65 days (top quartile) for 3+ quarters with no improvement
Assessment:
- ✅ This might be okay — You’ve reached optimization ceiling
- ⚠️ Or it’s complacency — There’s room to push further
Decision point: Is 65 days “good enough” or do you want to push for 55? Depends on your competitive strategy and resource investment.
🚫 Benchmarking Pitfalls to Avoid
Don’t sabotage your analysis with these common mistakes:
1. Comparing Apples to Oranges
The mistake: Phase 1 oncology studies ≠ Phase 3 cardiology studies
Why it fails: Different phases have different complexity, regulatory requirements, and timelines.
Fix: Always segment by phase AND therapeutic area when comparing.
2. Ignoring Sponsor-Specific Delays
The mistake: Blaming yourself for delays outside your control
Example: Sponsor takes 30+ days for internal contract review
Why it matters: Some sponsors are systematically slower. This isn’t your fault.
Fix: Track “site-controlled days” vs “sponsor-controlled days” separately. Report on what you can control.
3. Celebrating Speed Without Efficiency
The mistake: Bragging about 60 days with 50% idle time
Reality: 70 days with 85% efficiency is better — it means you’re executing well when the ball is in your court.
Fix: Always report both total cycle time AND efficiency rate.
4. Using Stale Data
The mistake: Comparing your 2025 data to 2020-2021 benchmarks
Why it fails: Pandemic-era data is skewed. Post-COVID patterns are different.
Fix: Use benchmarks from 2023+. If using older data, note it clearly.
5. Focusing Only on Total Cycle Time
The mistake: “We’re at 75 days, we’re good!”
Reality: Without phase-by-phase breakdowns, you don’t know WHERE the delays are.
Fix: Break down by phase: Feasibility → Budget/Contract → IRB → Startup
6. Cherry-Picking Good Studies
The mistake: Only tracking your fastest studies
Reality: This inflates your performance and masks real problems.
Fix: Track ALL studies. If you need to exclude outliers, document why and report separately.
7. Not Adjusting for Study Complexity
The mistake: Comparing a simple observational study to a complex interventional trial
Fix: Create complexity tiers:
- Tier 1: Observational, registry studies
- Tier 2: Standard interventional
- Tier 3: High-complexity (gene therapy, rare disease, first-in-human)
Communicating Benchmarks to Stakeholders
Different audiences need different views of your benchmark data.
For Leadership
What they care about:
- Bottom line: Are we competitive?
- Trend: Are we improving?
- ROI: Are our investments working?
How to present:
Create a simple executive dashboard:
Average Startup Cycle Time
↑ 15% vs Last Quarter
🎯 Target: <60 days by Q2
Faster than median
Rank: Top Quartile (25th %ile)
Active Efficiency Rate
(Industry avg: 60%)
Status: Above Average ✓
Talking points:
- “We’re in the top 25% of sites nationally”
- “Our process improvements saved 20 days per study”
- “At our current volume, this represents $X in efficiency gains”
For Operations Teams
What they care about:
- Where are the bottlenecks?
- What can WE control?
- What’s the action plan?
How to present:
Create a phase-by-phase breakdown:
| Phase | Our Time | Industry | Status | Owner |
|---|---|---|---|---|
| Feasibility | 5 days | 7 days | ✅ Fast | Clinical |
| Budget/Contract | 22 days | 18 days | ⚠️ Slow | Finance |
| IRB Submission | 8 days | 6 days | ⚠️ Slow | Regulatory |
| IRB Review | 21 days | 25 days | ✅ Fast | External |
| Startup Activities | 9 days | 12 days | ✅ Fast | Clinical |
Action Items:
- Finance: Investigate why budget/contract takes 22 vs 18 days
- Regulatory: Streamline IRB submission prep (target: 6 days)
- All: Maintain current performance in fast areas
For Sponsors (Building Credibility)
What they care about:
- Can this site deliver?
- Are they efficient?
- Will they meet timelines?
How to present:
🏆 Top Quartile Site Performance
Site Startup Cycle Time: 65 days (avg)
Industry Median: 89 days
Difference: 27% faster than typical sites
Recent Track Record (Last 12 Months):
- ✓ 15 studies activated
- ✓ 93% on-time or early startup
- ✓ 73% active efficiency rate
Phase-Specific Performance:
- Phase 1: 48 days (Top 20%)
- Phase 2: 62 days (Top 25%)
- Phase 3: 67 days (Top 25%)
Why we’re faster:
- → Dedicated startup team
- → Pre-negotiated contract templates
- → 48-hour feasibility response SLA
- → Streamlined IRB process
Your 30-60-90 Day Benchmarking Action Plan
Ready to implement benchmarking at your site? Here’s your step-by-step plan:
Days 1-30: Data Collection Phase
Week 1-2:
- Identify last 10-15 completed studies
- Pull startup dates for each phase
- Create tracking spreadsheet
- Categorize by phase and therapeutic area
Week 3-4:
- Calculate internal averages by phase
- Calculate quarter-over-quarter trends (if historical data available)
- Identify 2-3 studies for detailed efficiency analysis
- Document idle time sources
Deliverable: Internal benchmark baseline report
Days 31-60: Analysis & Comparison Phase
Week 5-6:
- Research external benchmarks (Tufts, TransCelerate, CenterWatch)
- Compare your averages to industry data
- Calculate efficiency rates for 2-3 sample studies
- Identify patterns and anomalies
Week 7-8:
- Create stakeholder-specific reports (Leadership, Operations, Sponsors)
- Prepare visualization (charts, dashboards)
- Draft findings document
- Identify top 3 improvement opportunities
Deliverable: Complete benchmark analysis with recommendations
Days 61-90: Action & Implementation Phase
Week 9-10:
- Present findings to leadership
- Present findings to operations team
- Get buy-in on improvement priorities
- Assign ownership for each initiative
Week 11-12:
- Implement quick wins (low-hanging fruit)
- Launch pilot improvement for #1 priority
- Set up quarterly benchmark review process
- Create ongoing tracking system
Week 13 (Day 91):
- Set quarterly targets
- Schedule Q+1 benchmark review meeting
- Document lessons learned
- Establish benchmarking as ongoing practice
Deliverable: Action plan in motion with measurable targets
FAQ: Your Benchmarking Questions Answered
A: Start where you are.
- With 1 quarter: You can do external comparison and efficiency analysis
- With 2 quarters: You can start to see directional trends
- With 3+ quarters: You can establish reliable internal benchmarks
Don’t wait for perfect data. Start tracking now, and your dataset will build over time.
Pro Tip: Even with limited internal data, you can benchmark against external sources immediately.
A: Document and decide.
Example: You have 10 studies averaging 70 days, but one took 145 days due to an IRB issue.
Options:
- Include it: Shows reality, but skews your average to 77.5 days
- Exclude it: More representative, but report it separately as “1 outlier excluded (145 days due to IRB special circumstances)”
Best practice: Report both with and without outliers: “Our average startup is 70 days (77.5 days including one outlier)”
Never: Just silently drop data without explanation.
A: Separate what you control from what you don’t.
Create two metrics:
1. Site-Controlled Cycle Time
Everything within your control: Feasibility response, Internal reviews, Budget/contract preparation (on your end), IRB submission prep, Startup execution
2. External Dependencies
What you’re waiting for: Sponsor contract review/approval, IRB review period, Third-party vendor setup
Report both:
- “Our site-controlled cycle time is 42 days (top quartile)”
- “External dependencies add 31 days (sponsor: 18, IRB: 13)”
This shows your efficiency while acknowledging constraints.
A: Yes, but flag it clearly.
Transitions create natural performance dips. That’s okay and expected.
How to handle:
- Continue tracking data
- Note the transition period in your analysis
- Report pre-transition, transition, and post-transition separately
Example:
- Q1 2024: 75 days (pre-transition)
- Q2 2024: 88 days (transition period – new CRA onboarding)
- Q3 2024: 68 days (post-transition)
This shows temporary dip + recovery, which is normal and demonstrates good management.
A: Yes! Three reasons:
- Maintain performance: Even competitive sites can regress without tracking
- Push for excellence: Top quartile → Top decile → Top 5%
- Credibility with sponsors: Data-backed performance claims win more studies
Think of it like fitness tracking: Even athletes track metrics. Being good doesn’t mean you stop measuring.
A: Quarterly for internal, annually for external.
Internal benchmarks:
- Recompute quarterly
- Look for trends over 3-4 quarters
- React to changes
External benchmarks:
- Industry data updates annually
- Check for new publications each year
- Major sources publish Q4 or Q1
Monthly tracking:
- Track individual study progress monthly
- Roll up to quarterly benchmarks
- Don’t over-react to monthly fluctuations
A: Segment your data.
Create separate benchmarks:
- Overall site average (for general comparison)
- Oncology studies
- Cardiology studies
- Rare disease studies
- etc.
Example reporting:
Overall Site Average: 70 days
By Therapeutic Area:
- Oncology: 65 days (12 studies)
- Cardiology: 72 days (8 studies)
- Rare Disease: 78 days (5 studies)
A: If they’re good, YES. If they’re improving, MAYBE. If they’re poor, WORK ON THEM FIRST.
When to share:
- ✅ Top quartile performance
- ✅ Significant improvement trend
- ✅ Competitive advantage to highlight
How to share:
- Include in site feasibility responses
- Feature in site profile/capabilities deck
- Mention in kickoff meetings
When to hold back:
- ⚠️ Bottom half performance
- ⚠️ Declining trends
- ⚠️ Significant variability
Fix first, then share. Don’t advertise poor performance.
Tools & Resources for Benchmarking
Free Public Benchmarks
Tufts CSDD
Center for the Study of Drug Development
- Annual reports on cycle times
- Gold standard for industry benchmarks
- Cost: $500-1500 for reports
TransCelerate BioPharma
- KPI benchmarks available to members
- Some public data available
- Large sponsor perspective
- Cost: Free for public data
CenterWatch
- Monthly newsletter with industry trends
- Annual benchmark reports
- Site-focused perspective
- Cost: Free newsletter, $300-800 for detailed reports
SCRS
Society for Clinical Research Sites
- Member-only benchmarking data
- Peer network comparisons
- Site-focused metrics
- Cost: $500-1500 annual membership
- Automated startup tracking
- Built-in benchmark comparisons
- Real-time dashboards
- Advarra OnCore CTMS
- Oracle Siebel CTMS
- WCG eResearch CTMS
- Extract data for analysis
- Tableau (advanced visualization)
- Power BI (Microsoft ecosystem)
- Google Data Studio (free)
- Tufts CSDD Outlook Report
- CenterWatch State of the Industry
- WCG IRB Benchmark Report
- SCRS member benchmarking data
When Benchmarking Goes Wrong: Cautionary Tales
Case Study 1: The Cherry-Picker
Site XYZ started benchmarking and proudly announced “55-day average startup!”
What they did: Only included their fastest 40% of studies, excluding anything over 70 days as “outliers.”
What happened: Sponsors selected them based on this claim, then experienced 85-day startups.
Consequence: Lost credibility, lost future opportunities, damaged reputation.
Lesson: Be honest. It’s better to say “70-day average with 20% at 55 days” than to mislead.
Case Study 2: The Apples-to-Oranges Comparator
Site ABC compared their Phase 1 oncology startup (48 days) to the published industry median (89 days) and claimed they were “45% faster.”
What they missed: The 89-day median includes all phases. Phase 1 industry median is 60-70 days.
What happened: Sponsors pointed out the flawed comparison, undermining their credibility.
Lesson: Always compare like to like. Phase-specific benchmarks matter.
Case Study 3: The Stale Data Trap
Site DEF used 2019-2020 benchmark data in late 2024.
What they missed: Pandemic-era data showed inflated timelines. 2024 industry has recovered.
What happened: They thought 95 days was “industry median” when current median is 85 days. They were slower than they realized.
Lesson: Use current data. Benchmarks evolve.
Case Study 4: The Efficiency Ignorer
Site GHI bragged about 60-day startups.
What they didn’t measure: Efficiency rate was only 40% (24 active days, 36 idle days).
What it revealed: They were fast only because sponsors and IRBs were fast. Their actual work took the same time as everyone else.
What happened: When they switched to a slower sponsor, their timelines ballooned to 105 days.
Lesson: Speed isn’t skill if it’s dependent on external factors. Measure efficiency.
Case Study 5: The Improvement Theater
Site JKL showed consistent 5% quarter-over-quarter improvement for 6 quarters.
What wasn’t disclosed: They started at 150 days (bottom 10%) and were still at 95 days after 6 quarters (below median).
What happened: Leadership celebrated “continuous improvement” while still being uncompetitive.
Lesson: Relative improvement matters, but so does absolute performance. Don’t celebrate your way from “terrible” to “mediocre.”
Takeaway
Benchmarking isn’t about bragging rights — it’s about clarity.
It tells you if your “fast” is actually efficient or just habitually slow.
You can’t improve what you haven’t compared.
The goal isn’t perfection. The goal is:
- Know where you stand (internal + external context)
- Identify opportunities (diagnostic patterns)
- Take action (focused improvements)
- Track progress (ongoing measurement)
Sites that benchmark systematically outperform those that don’t — not because measuring makes you faster, but because measurement drives focus, accountability, and continuous improvement.
What’s Next?
This post covered how to benchmark. Other Posts in this series – Metrics that matter:
- “5 Study Startup Metrics That Actually Predict Delays” (previous post)
- “How to Fix the Top 5 Study Startup Bottlenecks”
- “Building a Startup Metrics Dashboard Your Team Will Actually Use”
Want these delivered to your inbox? Subscribe to our study startup optimization series.
About TrialConnx: We help clinical research sites optimize study startup through process automation and real-time metrics tracking. Our platform is used by leading research sites to reduce startup cycle times and improve efficiency.
